American Society of Hematology

Fig. 4.

Inhibition of human ristocetin-induced platelet aggregation: Dose-response to combination of SNO-Glu and AR545C. Human PRP (2.5 × 108/mL) was incubated with increasing concentrations of AR545C followed by addition of 1.5 mg/mL ristocetin in the absence (▪) or presence of 2 concentrations of SNO-Glu: (□), 0.2 μmol/L SNO-Glu; (▵), 0.5 μmol/L SNO-Glu. (▴), Increasing concentrations of SNO-Glu in the absence of AR545C. Each point represents mean ± SEM of 3 experiments.

Inhibition of human ristocetin-induced platelet aggregation: Dose-response to combination of SNO-Glu and AR545C. Human PRP (2.5 × 10⁸/mL) was incubated with increasing concentrations of AR545C followed by addition of 1.5 mg/mL ristocetin in the absence (▪) or presence of 2 concentrations of SNO-Glu: (□), 0.2 μmol/L SNO-Glu; (▵), 0.5 μmol/L SNO-Glu. (▴), Increasing concentrations of SNO-Glu in the absence of AR545C. Each point represents mean ± SEM of 3 experiments.

This Feature Is Available To Subscribers Only